Association Between Remnant Cholesterol and Risk of Hyperuricemia: A
                    Cross-Sectional Study

Zhaoxiang Wang; Menghuan Wu; Han Yan; Shao Zhong; Ruijun Xu; Zhiyong Zhao; Qichao Yang

doi:10.1055/a-2299-2914

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 2024; 56(12): 882-889
DOI: 10.1055/a-2299-2914

Original Article: Endocrine Care

Association Between Remnant Cholesterol and Risk of Hyperuricemia: A Cross-Sectional Study

Authors

Zhaoxiang Wang

¹Department of Endocrinology, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, China
Menghuan Wu

²Department of Cardiology, Xuyi People's Hospital, Xuyi, China
Han Yan

³Department of Endocrinology, Affiliated Wujin Hospital of Jiangsu University, Wujin Clinical College of Xuzhou Medical University, Changzhou, China
Shao Zhong

¹Department of Endocrinology, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, China
Ruijun Xu

³Department of Endocrinology, Affiliated Wujin Hospital of Jiangsu University, Wujin Clinical College of Xuzhou Medical University, Changzhou, China
Zhiyong Zhao

³Department of Endocrinology, Affiliated Wujin Hospital of Jiangsu University, Wujin Clinical College of Xuzhou Medical University, Changzhou, China
Qichao Yang

³Department of Endocrinology, Affiliated Wujin Hospital of Jiangsu University, Wujin Clinical College of Xuzhou Medical University, Changzhou, China

Abstract

Remnant cholesterol (RC) is closely related to metabolic diseases. Our study aims to explore the relationship between RC and hyperuricemia. This cross-sectional study included 14 568 adults aged 20 years or older from the National Health and Nutrition Examination Survey (NHANES) conducted between 2007 and 2018 in the United States. RC is calculated by subtracting high-density lipoprotein cholesterol (HDL-c) and low-density lipoprotein cholesterol (LDL-c) from total cholesterol (TC). Hyperuricemia is defined by serum uric acid (SUA) levels≥7 mg/dl in men and≥6 mg/dl in women. The independent association between RC and hyperuricemia was evaluated. As the quartile range of RC levels increases, the prevalence of hyperuricemia also rises (7.84% vs. 13.71% vs. 18.61% vs. 26.24%, p<0.001). After adjusting for confounding factors, the fourth quartile of RC was associated with an increased risk of hyperuricemia compared with the first quartile (OR=2.942, 95% CI 2.473–3.502, p<0.001). Receiver Operating Characteristic (ROC) analysis shows that RC outperforms other single lipid indices in hyperuricemia. Further Restricted Cubic Splines (RCS) analysis suggests a nonlinear relationship between RC levels and hyperuricemia. Elevated RC levels were found to be linked to hyperuricemia. Further studies on RC hold promise for both preventing and addressing hyperuricemia.

Keywords

remnant cholesterol - hyperuricemia - NHANES - population-based study - nonlinear relationship

Full Text

References

References
1 Maiuolo J, Oppedisano F, Gratteri S. et al. Regulation of uric acid metabolism and excretion. Int J Cardiol 2016; 213: 8-14
2 Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 2020; 16: 380-390
3 Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. Rheumatology (Oxford) 2013; 52: 34-44
4 Crawley WT, Jungels CG, Stenmark KR. et al. U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia. Redox Biol 2022; 51: 102271
5 Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med 2017; 15: 123
6 Oral A, Sahin T, Turker F. et al. Relationship between serum uric acid levels and nonalcoholic fatty liver disease in non-obese patients. Medicina (Kaunas) 2019; 55: 600
7 Ahn JK. Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean. J Rheum Dis 2023; 30: 88-98
8 Stürzebecher PE, Katzmann JL, Laufs U. What is 'remnant cholesterol'?. Eur Heart J 2023; 44: 1446-1448
9 Wadström BN, Wulff AB, Pedersen KM. et al. Remnant cholesterol in the era of intensive lipid-lowering therapies. Eur Heart J 2023; 44: 3483
10 Mach F, Baigent C, Catapano AL. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188
11 Quispe R, Martin SS, Michos ED. et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. Eur Heart J 2021; 42: 4324-4332
12 Hu X, Liu Q, Guo X. et al. The role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus. Cardiovasc Diabetol 2022; 21: 117
13 Chen J, Su Y, Su X. et al. Remnant cholesterol has a non-linear association with non-alcoholic fatty liver disease. Diabetes Res Clin Pract 2023; 201: 110733
14 Zou Y, Kuang M, Zhong Y. et al. Remnant cholesterol can identify individuals at higher risk of metabolic syndrome in the general population. Sci Rep 2023; 13: 5957
15 Zou Y, Lan J, Zhong Y. et al. Association of remnant cholesterol with nonalcoholic fatty liver disease: a general population-based study. Lipids Health Dis 2021; 20: 139
16 Fang Y, Mei W, Wang C. et al. Dyslipidemia and hyperuricemia: a cross-sectional study of residents in Wuhu, China. BMC Endocr Disord 2024; 24: 2
17 Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821
18 Levey AS, Stevens LA, Schmid CH. et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
19 Cheng J, Sun J, Yao K. et al. A variable selection method based on mutual information and variance inflation factor. Spectrochim Acta A Mol Biomol Spectrosc 2022; 268: 120652
20 Sascău R, Clement A, Radu R. et al. Triglyceride-rich lipoproteins and their remnants as silent promoters of atherosclerotic cardiovascular disease and other metabolic disorders: a review. Nutrients 2021; 13: 1774
21 Jørgensen AB, Frikke-Schmidt R, West AS. et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 2013; 34: 1826-1833
22 Sandesara PB, Virani SS, Fazio S. et al. The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocr Rev 2019; 40: 537-557
23 Huang H, Xie J, Zeng Y. et al. Remnant cholesterol independently Ppredicts the development of nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2023; 108: 2907-2915
24 Szili-Torok T, Sokooti S, Osté MCJ. et al. Remnant lipoprotein cholesterol is associated with incident new onset diabetes after transplantation (NODAT) in renal transplant recipients: results of the TransplantLines Biobank and cohort Studies. Cardiovasc Diabetol 2022; 21: 41
25 Pillinger MH, Bangalore S, Klein AB. et al. Cardiovascular disease and gout: real-world experience evaluating patient characteristics, treatment patterns, and health care utilization. J Manag Care Spec Pharm 2017; 23: 677-683
26 Hu X, Rong S, Wang Q. et al. Association between plasma uric acid and insulin resistance in type 2 diabetes: a Mendelian randomization analysis. Diabetes Res Clin Pract 2021; 171: 108542
27 Ohnishi H, Saitoh S, Takagi S. et al. Relationship between insulin-resistance and remnant-like particle cholesterol. Atherosclerosis 2002; 164: 167-170
28 Shalaurova I, Connelly MA, Garvey WT. et al. Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance. Metab Syndr Relat Disord 2014; 12: 422-429
29 Garvey WT, Kwon S, Zheng D. et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52: 453-462
30 Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46: 733-749
31 Haas ME, Attie AD, Biddinger SB. The regulation of ApoB metabolism by insulin. Trends Endocrinol Metab 2013; 24: 391-397
32 Song Y, Liu J, Zhao K. et al. Cholesterol-induced toxicity: an integrated view of the role of cholesterol in multiple diseases. Cell Metab 2021; 33: 1911-1925
33 Conen D, Wietlisbach V, Bovet P. et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health 2004; 4: 9
34 Deedwania PC, Stone PH, Fayyad RS. et al. Improvement in renal function and reduction in serum uric acid with intensive statin therapy in older patients: a post hoc analysis of the SAGE trial. Drugs Aging 2015; 32: 1055-1065
35 Akbari A, Razmi M, Rafiee M. et al The effect of statin therapy on serum uric acid levels: a systematic review and meta-analysis. Curr Med Chem 2023;
36 Zhou S, Wu L, Si H. et al. Longitudinal association between uric acid and incident sarcopenia. Nutrients 2023; 15: 3097
37 Tarantino G, Sinatti G, Citro V. et al. Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression?. Intern Emerg Med 2023; 18: 1887-1895
38 Bi B, Dong X, Yan M. et al. Dyslipidemia is associated with sarcopenia of the elderly: a meta-analysis. BMC Geriatr 2024; 24: 181

Supplementary Material

Supplementary Material (PDF)